The results of clinical trials that the AstraZeneca Corona 19 vaccine has a limited preventive effect on mutations originating in South Africa, Reuters and others reported.
As a result of conducting phase 1 and 2 trials of 2,26 people at Oxford University and University of South Africa, it was found that the two doses of the AstraZeneca vaccine did not prevent the onset of mild and moderate symptoms caused by mutations in South Africa. .
The researchers explained that the severity of the South African mutation and its effectiveness in preventing hospitalization or death cannot be determined yet.
However, none of the clinical trial participants were reported to have been hospitalized or died.
AstraZeneca added that the neutralizing antibody activity of its vaccine was shown to be the same as that of other vaccines, which would prevent the severe disease caused by mutations in South Africa.
This clinical trial is limited in its small size, and the thesis has not yet gone through peer review, an expert review process.
Meanwhile, the University of Oxford says the AstraZeneca vaccine is effective against the UK mutation.